Scholarlink

Purpose <p>To evaluate the correlation between prostate morphological measurements and changes in ejaculatory function during short-term tamsulosin therapy in men with benign prostatic hyperplasia (BPH).</p> Methods <p>This prospective study included 214 sexually active men with moderate-to-severe lower urinary tract symptoms (LUTS) who received tamsulosin 0.4&#xa0;mg/day for eight weeks. Patients with prior treatment for BPH or pre-existing sexual dysfunction were excluded. Symptom severity and ejaculatory function were evaluated using the International Prostate Symptom Score (IPSS) and the Male Sexual Health Questionnaire–Ejaculatory Dysfunction Short Form (MSHQ-EjD-SF). Prostate morphological measurements, including overall dimensions and intravesical prostatic protrusion (IPP), were obtained by transabdominal ultrasonography. Correlations between changes in MSHQ-EjD scores (ΔMSHQ-EjD) and clinical or anatomical variables were assessed using Spearman’s rank coefficients.</p> Results <p>After eight weeks of treatment, the median IPSS significantly decreased from 18 to 14 (<i>p</i> &lt; 0.001) and Qmax increased from 9.2 to 14.0 mL/s (<i>p</i> &lt; 0.001). The median MSHQ-EjD-SF score declined from 11 to 7 (<i>p</i> &lt; 0.001), while higher ejaculatory bother scores were observed after treatment. ΔMSHQ-EjD was negatively correlated with IPP (ρ = −0.386), prostate length (ρ = −0.250), and age (ρ = −0.334) (all <i>p</i> &lt; 0.01). Patients with IPP &gt; 10&#xa0;mm showed a less pronounced decline in ejaculatory function compared with lower IPP grades (<i>p</i> &lt; 0.001).</p> Conclusions <p>Tamsulosin improved urinary symptoms but was associated with a decline in ejaculatory function. Prostate morphological characteristics, particularly IPP &gt; 10&#xa0;mm and longer prostate length, were associated with a less pronounced decline in ejaculatory function. Although these correlations were modest, the findings may help contextualize the relationship between prostate anatomy and tamsulosin-related ejaculatory changes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Correlation between intravesical prostatic protrusion and ejaculatory dysfunction after tamsulosin treatment in men with BPH

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月17日

查看全文
  • Cem Tuğrul Gezmiş,
  • Nusret Can Çilesiz,
  • Veli Huzeyfe Kartal,
  • Mahmut Kemal Altan,
  • Basri Çakıroğlu,
  • Mustafa Bahadır Can Balcı

摘要

Purpose

To evaluate the correlation between prostate morphological measurements and changes in ejaculatory function during short-term tamsulosin therapy in men with benign prostatic hyperplasia (BPH).

Methods

This prospective study included 214 sexually active men with moderate-to-severe lower urinary tract symptoms (LUTS) who received tamsulosin 0.4 mg/day for eight weeks. Patients with prior treatment for BPH or pre-existing sexual dysfunction were excluded. Symptom severity and ejaculatory function were evaluated using the International Prostate Symptom Score (IPSS) and the Male Sexual Health Questionnaire–Ejaculatory Dysfunction Short Form (MSHQ-EjD-SF). Prostate morphological measurements, including overall dimensions and intravesical prostatic protrusion (IPP), were obtained by transabdominal ultrasonography. Correlations between changes in MSHQ-EjD scores (ΔMSHQ-EjD) and clinical or anatomical variables were assessed using Spearman’s rank coefficients.

Results

After eight weeks of treatment, the median IPSS significantly decreased from 18 to 14 (p < 0.001) and Qmax increased from 9.2 to 14.0 mL/s (p < 0.001). The median MSHQ-EjD-SF score declined from 11 to 7 (p < 0.001), while higher ejaculatory bother scores were observed after treatment. ΔMSHQ-EjD was negatively correlated with IPP (ρ = −0.386), prostate length (ρ = −0.250), and age (ρ = −0.334) (all p < 0.01). Patients with IPP > 10 mm showed a less pronounced decline in ejaculatory function compared with lower IPP grades (p < 0.001).

Conclusions

Tamsulosin improved urinary symptoms but was associated with a decline in ejaculatory function. Prostate morphological characteristics, particularly IPP > 10 mm and longer prostate length, were associated with a less pronounced decline in ejaculatory function. Although these correlations were modest, the findings may help contextualize the relationship between prostate anatomy and tamsulosin-related ejaculatory changes.